Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study

Abroad (travel likely)RecruitingPHASE4

Conditions

Crohn Disease (CD) · Intensification

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Chu Amiens Picardie, Amiens, France

Study leads

Mathurin Fumery, Investigator
Principal Investigator
Hospital of Amiens, France

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD

Crohn Disease

Abroad (travel likely)RecruitingPHASE4

Orlando, United States · Salt Lake City, United States

Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

Crohn Disease (CD)

Abroad (travel likely)RecruitingPHASE4

Brest, France · Clermont-Ferrand, France

De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis

Crohn Disease (CD) · Ulcerative Colitis (UC)

Abroad (travel likely)RecruitingPHASE4

Montreal, Canada

Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease

Crohn Disease · Child, Only · Biologic; Inadequate

Abroad (travel likely)RecruitingPHASE4

Rotterdam, Netherlands